Nephrology Consultants LLC | Huntsville, AL

Research site

(Unclaimed)

Location

2780 Bob Wallace Avenue, SW, Huntsville, Alabama, United States of America

Site insights

Top conditions

Top treatments

BI 764198

Retatrutide

Empagliflozin

Finerenone

BI 685509

Bardoxolone Methyl

VX-147

Zetomipzomib

Phosphate

LY3841136

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 30 total trials

New

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk (ENLIGHTEN-10)

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overwei...

Begins enrollment in 1 month

Overweight

Obesity

Drug: Eloralintide

Drug: Placebo

A Study of Zigakibart in Adults With IgA Nephropathy

Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy

Active, not recruiting

Immunoglobulin A Nephropathy

IgA Nephropathy

Drug: BION-1301

Drug: Placebo

Locations recently updated

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

PODOMOUNT-pFSGSThis study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of...

Enrolling

Focal Segmental Glomerulosclerosis

Drug: BI 764198

Drug: Placebo

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study.Part 1...

Enrolling

End Stage Kidney Disease

Drug: Placebo

Drug: CSL300

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and ren...

Active, not recruiting

Type 2 Diabetes

Drug: Retatrutide

Drug: Placebo

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease (AMPLITUDE)

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants...

Active, not recruiting

Proteinuric Kidney Disease

Drug: VX-147

Drug: Placebo

Locations recently updated

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

This study is open to adults with certain kidney conditions, including secondary focal segmental glomerulosclerosis (sFSGS), treatment-resistant prim...

Enrolling

Proteinuric Kidney Diseases

Drug: Placebo matching BI 764198

Drug: BI 764198

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

The purpose of this study is to assess the safety and efficacy of up to 2 REACT/rilparencel injections in participants with T2DM and CKD.

Active, not recruiting

Chronic Kidney Diseases

Type 2 Diabetes Mellitus

Biological: Renal Autologous Cell Therapy (REACT/ rilparencel)

Procedure: Sham Comparator

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Active, not recruiting

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo